Sign in

Information, not a decision

Gastric and oesophageal cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation.

Data as of 19 Nov 2026

Open trials (1484)

Registry IDPhaseTrialStatus
NCT06172478Phase 2A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruiting
NCT07942285Phase 3Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5Not yet recruiting
NCT06253871Phase 1/2A Phase 1/2 Study of IAM1363 in HER2 CancersRecruiting
NCT07943533Phase 2HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric CancerNot yet recruiting
NCT07903415Phase 1A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.Recruiting
NCT07939230Phase 1Evaluation of FLT3L Armoured CAR T-cells in HER2 Expressing Malignant Diseases in AdultsNot yet recruiting
NCT07938021Phase 2HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal CancersNot yet recruiting
NCT06324357Phase 1/2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruiting
NCT07730021Phase 1/2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruiting
NCT07277413Phase 1A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsRecruiting
NCT07939204Phase 2A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Failure of or Progression on ImmunotherapyNot yet recruiting
NCT06469944Phase 1/2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Recruiting

1472 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

Guidelines

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 19 Nov 2026

https://frontlightresearch.com/en/doctor/gastric-and-esophageal-cancer/tumor-board